Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2018
September 2018, Vol 8, No 9
September 2018, Vol 8, No 9
Cannabis for Symptom Management in Cancer: Do You Know What Your Patients Are Using?
By
Meg Barbor, MPH
Medicinal Cannabis
,
Symptom Management
Patients with cancer are increasingly using cannabinoids (the chemical component of cannabis) to treat many symptoms, and a minority of them even take cannabis as a treatment for the cancer itself. Recent surveys have revealed that up to 25% of patients with cancer take some form of cannabis, but oncologists and other medical providers are often unaware that their patients are using medical (or recreational) cannabis.
Read More ›
Dispelling Misconceptions About HCC Coding
By
Karyn M. Dyehouse, MD
Coding and Billing
,
Reimbursement
Oncologists are operating in a whole new world as healthcare transitions to value-based care. To thrive in this emerging environment, providers must understand the many details involved in how value-based models work.
Read More ›
MSI-H a Marker for Lynch Syndrome, a More Common Condition Than Generally Expected
By
Wayne Kuznar
Biomarkers
Tumors with high microsatellite instability (MSI-H) are predictive of Lynch syndrome. The recent approval of the first immunotherapies for use in patients with MSI-H or with mismatch repair-deficiency (dMMR) in solid tumors is now leading to routine testing for MSI-H or dMMR in patients with advanced solid tumors.
Read More ›
Managing Cancer-Related Fatigue and Insomnia in Patients and Caregivers
By
Meg Barbor, MPH
Symptom Management
Cancer-related fatigue and insomnia frequently co-occur among patients with cancer, and emerging data have demonstrated that caregivers of patients with cancer also have a high symptom burden, with elevated rates of depression, sleep disturbance, and fatigue
Read More ›
Building on the Successes of Cancer Immunotherapy
By
Charles Bankhead
Immunotherapy
Learning how to activate and harness the immune system—the body’s built-in defense against disease—has brought the field of oncology to the cusp of a cure for at least some, if not many, types of cancer, according to an international authority in immuno-oncology.
Read More ›
Timing of Palliative Care Consults Key in Elderly Patients with Pancreatic Cancer
By
Chase Doyle
Palliative Care
A claims analysis of elderly patients with pancreatic cancer has shown that those receiving early palliative care consultations had lower healthcare utilization than patients who received late palliative care.
Read More ›
Best Practices: Evolving Understanding of Molecular Diagnostics and Biomarkers in Lung Cancer
By
Geoff Oxnard, MD
;
Lauren Ritterhouse, MD, PhD
2018 ASCO Highlights
,
Biomarkers
,
Interview with the Innovators
At ASCO 2018,
Oncology Practice Management
(
OPM
) discussed the current state of genetics and genomic testing, the increasing understanding of biomarkers, and how they influence the treatment of patients with lung cancer.
Read More ›
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
By
Phoebe Starr
Emerging Therapies
A novel oral agent (BLU-667) that targets
RET
genetic alterations, achieved durable disease control and was safe in patients with lung or thyroid cancers and
RET
mutations, as demonstrated by the first-in-human phase 1 clinical trial ARROW.
Read More ›
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
By
Phoebe Starr
Emerging Therapies
,
Immunotherapy
A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes